EW News & Events

Edwards Lifesciences announced the appointment of Theodora Mistras as the company's corporate vice president and CFO, effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor's degree in international studies from the University of Pennsylvania and a bachelor's degree in economics from the Wharton School.

Edwards Lifesciences announced 10-year results from the Commence aortic trial, reinforcing the long-term durability and sustained performance of its proprietary Resilia tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. At 10 years, Commence trial data showed that patients treated with Edwards' surgical valves featuring Resilia tissue experienced: 97.9% freedom from structural valve deterioration, SVD; 97.8% freedom from reoperation due to SVD; 98.6% freedom from non-structural valve dysfunction; Sustained hemodynamic performance, including stable gradients and effective orifice area over time